Navigation Links
Silence Therapeutics Announces Subscription and Open Offer to Raise up to £5.7 Million
Date:7/11/2012

Darwin. Following delivery of a subscription notice, Darwin will subscribe and the Company will allot to Darwin new Ordinary Shares in Silence.

The subscription price for any Ordinary Shares to be subscribed by Darwin under a subscription notice will be at a 5 per cent. discount to  the average of the three lowest reference prices where the reference prices will be the volume weighted average price of Ordinary Shares for each of 15 trading days following delivery of a subscription notice (the "Pricing Period"). Silence is also obliged to specify in each subscription notice a minimum price (the "Floor Price") below which Ordinary Shares will not be issued to Darwin. The Company will have the right to modify that Floor Price at any time with the consent of Darwin during the relevant Pricing Period. The number of Ordinary Shares issued on each draw down may not exceed 25 per cent. of the issued Ordinary Shares as enlarged by the issue.

The maximum number of Ordinary Shares which may be issued under any individual subscription notice will be 400 per cent. of  the average daily trading volume of Silence's Ordinary Shares over the 15 trading days preceding the issue of the relevant subscription notice. The number of shares to be issued may be reduced in certain circumstances, including where the Floor Price is not maintained, the Company's shares not being traded or the Company having suffered a material adverse effect during the Pricing Period.  There is an over-allotment facility available to the Company under which the Company may authorise Darwin at Darwin's discretion to increase the amount of draw down by up to the aggregate undrawn amount under the Equity Finance Facility.

The issuance of a subscription notice is conditional upon the satisfaction of certain subscription notice conditions (the "Subscription Notice Conditions") which have been agreed between Darwin and the Company. Any subscription notice which Silence may issue wi
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
2. Silence Therapeutics Announces Board Changes and Appointment of New Chief Executive Officer
3. Silence Therapeutics Additional Listing
4. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
5. Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
6. Nektar Therapeutics Announces Private Placement of $125 Million of Senior Secured Notes Due in 2017
7. Bio-Innovator Saneron CCEL Therapeutics Supports Cryo-Cell International Leadership and Board of Directors in Proxy Contest
8. Global Neuroendocrine Carcinoma Therapeutics Market To Reach $475m By 2019 - Report
9. United Therapeutics Announces Additional $100 Million Share Repurchase Program
10. Healthpoint Biotherapeutics To Create State-of-the-Art Cell Sciences Manufacturing Facility
11. ResearchMoz: Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar- Market Research Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 22, 2014   Synthetic Biologics, Inc. ... pathogen-specific therapies for serious infections and diseases, ... today announced positive topline safety and tolerability ... of SYN-004, the Company,s investigational oral beta-lactamase ... difficile (C. difficile) infection, antibiotic-associated diarrhea ...
(Date:12/22/2014)... 22, 2014  Alternative Energy & Environmental Solutions, ... signed a letter of intent to acquire BioTechPharma ... patented a nanotechnology-based development platform used to create ... rapid on-site collection and testing to identify infectious ... in an immediate, non-invasive and cost-effective manner. ...
(Date:12/22/2014)... MISSION VIEJO, Calif. , Dec. 22, 2014 /PRNewswire/ ... announce that CoPatient, an online medical bill review and ... newest offering in the FREE WellCard Savings discount health ... a medical bill that was more than they expected ... help members reduce health care costs, WellCard Savings is ...
(Date:12/22/2014)... ITRA Global, one of the largest organizations ... estate, has further expanded its global reach with the ... Western Australia, reports Mylinda Vick, CCIM, Chairman of the ... / ACORPP (Australian Corporate Property and Projects) , is ... services to a wide range of clients in the ...
Breaking Biology Technology:Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5ALNE Announces Intention To Acquire BioTechPharma 2WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2
... that it has received orders for the sale of ... far in its initial sales push,being led by new ... current efforts, shall announce such sales as and,when they ... an award-winning life sciences company focused on,the monitoring and ...
... 20 AMDL, Inc. (Amex:,ADL), headquartered in ... Jilin, China, through its wholly owned subsidiary ... company that,engages in the development, manufacture and ... announced today that JPI has a,new product ...
... Pharmaceuticals,Inc. (NASDAQ: ANPI , TSX: ANP), a global ... in the UBS Global Life,Sciences Conference, which is being ... On Monday, September 24, 2007 at 8:30am ET, Dr. ... give a 25-minute,presentation. A link to the live ...
Cached Biology Technology:Signalife Achieves $1.98 Million Sales Orders Thus Far 2AMDL's Jade Pharmaceutical Subsidiary Announces New Product Strategy; Six New Products, Including One With Sales Projected at Upwards of $10 Million, Under Development 2Angiotech to participate in UBS Global Life Sciences Conference 2Angiotech to participate in UBS Global Life Sciences Conference 3
(Date:12/17/2014)... YORK , Dec. 15, 2014  HITLAB ... Good Clinical Practices (GCP) audit to confirm its ... (FDA) regulations. This accomplishment enables HITLAB to conduct ... utilizing the highest principles for patient safety and ... improve global healthcare access, quality, and delivery with ...
(Date:12/17/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) ... Chemical Sensor Market 2015-2019" report to their ... One major trend upcoming in this ... in biomedical applications. Chemical sensors help in recording ... during surgical procedures. The Global Chemical Sensor market ...
(Date:12/15/2014)... Dec. 12, 2014 Research and Markets ... of the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition ... individuals. Facial recognition system measures the overall facial ... edges, mouth, and the distance between eyes. Facial ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... San Diego Cytori Therapeutics (NASDAQ: CYTX) announced ... from APOLLO, the Company,s European clinical trial evaluating ... with acute myocardial infarction (heart attack or AMI), ... the American College of Cardiology . The APOLLO ...
... of which are preventable via vaccines readily available in the ... of death for children in sub-Saharan Africa. ... funded by a $5.8 million grant aims to help prevent ... vaccine use and development. Funded by the Bill & Melinda ...
... the causes of the obesity epidemic in Aboriginal children ... factors that shape the Aboriginal community. A review article ... emphasizes that early childhood obesity prevention efforts should begin ... on breastfeeding initiatives and nutrition in the early childhood ...
Cached Biology News:Adipose stem cell heart attack trial data published in JACC 2$5.8 million Gates grant targets child-killing bacteria diseases in Africa 2
... volume pipetting is increasingly essential for ... DNA sequencing and other biochemical applications. ... and precision unparalleled in the industry. ... of all aspirated,and dispensed volumes , ...
... the rapid isolation of DNA from high melt ... the spin filter, centrifuge for 3 minutes, and ... is no need to melt agarose or use ... be used for buffer exchange, primer removal from ...
Request Info...
Guinea Pig Complement...
Biology Products: